文献速递临床试验与 GCP

卡培他滨节拍化疗作为转移性结直肠癌维持治疗非劣效于常规化疗的研究

A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer.
PubMed 文献 · Trials · 2020-03-06

本研究为前瞻性随机开放标签II期临床试验,旨在证明卡培他滨节拍化疗在转移性结直肠癌一线化疗16-18周后缓解患者的维持治疗中非劣效于常规剂量化疗。主要终点为随机后疾病控制时间和入组后无进展生存期,每组计划样本量79例,研究于2018年1月1日开始,持续36个月。

要点

  • 节拍化疗可能提供低毒高效的维持治疗选择
  • 主要终点为疾病控制时间和无进展生存期
  • 每组计划样本量79例,研究周期36个月

核心结论

  • 卡培他滨节拍化疗作为维持治疗可能非劣效于常规化疗,但需试验结果验证。

研究设计与样本

  • 前瞻性、随机、开放标签、II期临床试验。
  • 入组标准为转移性结直肠癌患者经16-18周标准双药化疗诱导后缓解。
  • 随机分为卡培他滨节拍化疗组或标准剂量组。
  • 每组计划样本量79例,研究于2018年1月1日开始,持续36个月。

关键数值与推荐

  • 主要终点为随机后疾病控制时间和入组后无进展生存期。
  • 次要终点包括总生存期、安全性和生活质量。
  • 样本量每组79例。

临床怎么用

  • 为转移性结直肠癌患者提供低毒、经济、个体化的维持治疗策略参考。

局限性

  • 研究为II期临床试验,样本量有限,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study is to demonstrate that capecitabine metronomic chemotherapy is non-inferior to capecitabine conventional chemotherapy as maintenance treatment, in patients who have responded to 16-18 weeks first-line chemotherapy in metastatic colorectal cancer (mCRC). METHODS: The study design is a prospective, randomized, open label, phase II clinical trial. Those patients with mCRC who respond well after 16-18 weeks of standard doublet chemotherapy as induction may be enrolled into this study, and randomly assigned to the capecitabine metronomic group or standard dosage group. The duration of disease control after randomization and progression-free survival after enrollment are the primary endpoints. Overall survival, safety, and quality of life are the secondary endpoints. The sample size required to achieve the research objectives of this project is 79 patients in each group. The study recently started on 1 January 2018, and will last for 36 months. DISCUSSION: This project is intended to study the efficacy and safety of capecitabine metronomic chemotherapy in the maintenance treatment of advanced colorectal cancer, and to explore the strategy of "low toxicity, high efficiency, economy, and individualization", which is suitable for China's national conditions and pharmacoeconomics. It has great prospects for clinical application and a clear socioeconomic value. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03158610. Registered on 15 May 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Shi M, Ma T, Xi W, et al. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. Trials. 2020. PMID: 32143730. doi:10.1186/s13063-020-4194-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。